146 related articles for article (PubMed ID: 31406250)
1. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Nitta RT; Bolin S; Luo E; Solow-Codero DE; Samghabadi P; Purzner T; Aujla PS; Nwagbo G; Cho YJ; Li G
Oncogene; 2019 Oct; 38(42):6867-6879. PubMed ID: 31406250
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
[TBL] [Abstract][Full Text] [Related]
3. Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Faoro D; von Bueren AO; Shalaby T; Sciuscio D; Hürlimann ML; Arnold L; Gerber NU; Haybaeck J; Mittelbronn M; Rutkowski S; Hegi M; Grotzer MA
J Neurooncol; 2011 May; 103(1):59-69. PubMed ID: 20820873
[TBL] [Abstract][Full Text] [Related]
4. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma.
Liu X; Chen J; Li W; Hang C; Dai Y
Transl Oncol; 2020 Jan; 13(1):70-78. PubMed ID: 31810002
[TBL] [Abstract][Full Text] [Related]
6. Overcoming multiple drug resistance mechanisms in medulloblastoma.
Othman RT; Kimishi I; Bradshaw TD; Storer LC; Korshunov A; Pfister SM; Grundy RG; Kerr ID; Coyle B
Acta Neuropathol Commun; 2014 May; 2():57. PubMed ID: 24887326
[TBL] [Abstract][Full Text] [Related]
7. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Villamañan L; Martínez-Escardó L; Arús C; Yuste VJ; Candiota AP
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810611
[TBL] [Abstract][Full Text] [Related]
8. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
9. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
10. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
11. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
Nitta RT; Luo EJ; Lim M; Li G
J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
[TBL] [Abstract][Full Text] [Related]
12. Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway.
Nitta RT; Gholamin S; Feroze AH; Agarwal M; Cheshier SH; Mitra SS; Li G
Oncogene; 2015 Jul; 34(28):3688-99. PubMed ID: 25241897
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
15. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
16. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Daniel RA; Rozanska AL; Mulligan EA; Drew Y; Thomas HD; Castelbuono DJ; Hostomsky Z; Plummer ER; Tweddle DA; Boddy AV; Clifford SC; Curtin NJ
Br J Cancer; 2010 Nov; 103(10):1588-96. PubMed ID: 20978505
[TBL] [Abstract][Full Text] [Related]
19. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
